Arbeitsgruppe Pankreaskarzinom - Studien
Pankreaskarzinom, metastasiert, 1st-line

AIO-assoziierte Studie
www.clinicaltrials.gov zur Studie

AIO-PAK-0317/ass: A multicenter randomized phase II/III study to determine the optimal first line chemotherapy regimen in medically fit patients diagnosed with metastatic pancreatic cancer (FOOTPATH)
  ---in Rekrutierung---

AIO-Studie

zur Studie

AIO-PAK-0219:  Intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled phase 3 trial  (METAPANC)
  ---in Vorbereitung---

AIO-Studie
www.clinicaltrials.gov zur Studie

AIO-PAK-0114: Induction treatment with nab-paclitaxel/gemcitabine for first-line treatment of metastatic pancreatic cancer followed by either alternating application of gemcitabine monotherapy and nab-paclitaxel/gemcitabine or continuing application of nab-paclitaxel/gemcitabine: A randomized phase II study (ALPACA)
  ---in Rekrutierung---

AIO-Studie
www.clinicaltrials.gov zur Studie

AIO-PAK-0118: A multi-center, phase I/II study of sequential epigenetic and immune targeting in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. (SEPION)  
  ---in Vorbereitung ---

AIO-Studie für weitere Zentren offen www.clinicaltrials.gov zur Studie

AIO-PAK-0120/xx: MAintenance ThErapy vs. Observation in FOLFIRINOX treated metastatic Pancreatic ductal adenocarcinoma patients - A prospective, randomized multi-center phase II AIO trial (MATEO-Panc)
  ---in Vorbereitung ---
Pankreaskarzinom – palliative Therapie, 2nd-line

AIO-Studie
www.clinicaltrials.gov zur Studie

AIO-PAK-0216: Second- line therapy with Nal-IRI after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of first-line therapy - PREDICT
  ---in Rekrutierung---

AIO-Studie
www.clinicaltrials.gov zur Studie

AIO-PAK-0116: A health service research study to investigate survival of metastatic pancreatic cancer patients after sequential chemotherapy: An AIO phase II cross over trial (PANTHEON)
  ---in Rekrutierung---
Pankreaskarzinom, local begrenzt, inoperabel

AIO-assoziierte Studie
www.clinicaltrials.gov zur Studie

Randomisierte Phase-III-Studie zum Stellenwert einer Radiochemotherapie nach Induktionschemotherapie beim lokal begrenzten, inoperablen Pankreaskarzinom: Chemotherapie gefolgt von Radiochemotherapie im Vergleich zur alleinigen Chemotherapie - CONKO-007
  ---in Rekrutierung---
Pankreaskarzinom - Operable Patienten

AIO-assoziierte Studie
www.clinicaltrials.gov zur Studie

AIO-YMO/PAK-0218/ass - PROJECTION - Prognostic role of circulating tumor DNA in resectable pancreatic cancer
  ---in Vorbereitung---

AIO-assoziierte Studie
  zur Studie

AIO-PAK-0121/ass - An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature - ESPAC-6
  ---in Vorbereitung---
Pankreaskarzinom, neoadjuvant, perioperativ

AIO-assoziierte Studie für weitere Zentren offen
zur Studie

AIO-PAK-0220/ass/xx: Neoadjuvant treatment in frail patients with pancreatic adenocarcinoma - A prospective, parallel-group, randomized multi-center Phase II AIO/CHIR-Net Trial (FrailPanc)
  ---in Vorbereitung---
Registerstudie

AIO-Studie für weitere Zentren offen
  zur Studie

AIO-YMO/PAK-0215 Eine multizentrische Registerstudie zur Erfassung klinischer, epidemiologischer und biologischer Parameter beim duktalen Adenokarzinom des Pankreas (PDAC, PaCaReg)
  ---in Rekrutierung---

LETZTE AKTUALISIERUNG DIESER SEITE AM: 17.11.2020